These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 6970620)

  • 1. Progressing Moloney sarcoma virus (M-MSV) induced tumors: effect of host's immunomanipulation.
    Collavo D; Zanovello P; Biasi G; Chieco-Bianchi L
    Cell Mol Biol Incl Cyto Enzymol; 1980; 26(2):155-8. PubMed ID: 6970620
    [No Abstract]   [Full Text] [Related]  

  • 2. Functional activity in vivo of effector T cell populations. III. Protection against Moloney murine sarcoma virus (M-MSV)-induced tumors in T cell deficient mice by the adoptive transfer of a M-MSV-specific cytolytic T lymphocyte clone.
    Cerundolo V; Lahaye T; Horvath C; Zanovello P; Collavo D; Engers HD
    Eur J Immunol; 1987 Feb; 17(2):173-8. PubMed ID: 3030766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T cell tolerance in moloney-murine leukemia virus (M-MuLV) carrier mice: low cytotoxic T lymphocyte precursor frequency and absence of suppressor T cells in carrier mice with Moloney-murine sarcoma (M-MSV)-induced tumors.
    Collavo D; Ronchese F; Zanovello P; Biasi G; Chieco-Bianchi L
    J Immunol; 1982 Feb; 128(2):774-9. PubMed ID: 6459385
    [No Abstract]   [Full Text] [Related]  

  • 4. Cell-mediated immunity to Moloney sarcoma virus in mice. II. Analysis of antigenic specificities involved in T lymphocyte-mediated in vivo rejection of murine sarcoma virus-induced tumors.
    Gorczynski RM; Knight RA
    Eur J Immunol; 1975 Feb; 5(2):148-55. PubMed ID: 1086221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of Moloney sarcoma virus immunity following sensitization with attenuated virus.
    Wood GW
    Cancer Res; 1976 Dec; 36(12):4552-7. PubMed ID: 1000500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T lymphocyte requirement for MSV tumour prevention or regression.
    Collavo D; Colombatti A; Chieco-Bianchi L
    Nature; 1974 May; 249(453):169-70. PubMed ID: 4545519
    [No Abstract]   [Full Text] [Related]  

  • 7. Retrovirus-induced changes in major histocompatibility complex antigen expression influence susceptibility to lysis by cytotoxic T lymphocytes.
    Flyer DC; Burakoff SJ; Faller DV
    J Immunol; 1985 Oct; 135(4):2287-92. PubMed ID: 2411792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibody against IFN-gamma inhibits Moloney murine sarcoma virus-specific cytotoxic T lymphocyte differentiation.
    Zanovello P; Vallerani E; Biasi G; Landolfo S; Collavo D
    J Immunol; 1988 Feb; 140(4):1341-4. PubMed ID: 2830339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy and chemotherapy of Moloney sarcoma virus-induced tumors in mice.
    Fefer A
    Cancer Res; 1969 Dec; 29(12):2177-83. PubMed ID: 5369675
    [No Abstract]   [Full Text] [Related]  

  • 10. Primary and secondary in vitro generation of cytolytic T lymphocytes in the murine sarcoma virus system.
    Plata F; Cerottini JC; Brunner KT
    Eur J Immunol; 1975 Apr; 5(4):227-33. PubMed ID: 185057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of proliferation of lymphoma cells and T lymphocytes by suppressor cells from spleens of tumor-bearing mice.
    Kirchner H; Muchmore AV; Chused TM; Holden HT; Herberman RB
    J Immunol; 1975 Jan; 114(1 Pt 1):206-10. PubMed ID: 122986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moloney murine leukemia virus tolerance in anti-CD4 monoclonal antibody-treated adult mice.
    Biasi G; Facchinetti A; Panozzo M; Zanovello P; Chieco-Bianchi L; Collavo D
    J Immunol; 1991 Oct; 147(7):2284-9. PubMed ID: 1833453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T lymphocyte tolerance and early appearance of virus-induced cell surface antigens in Moloney-murine leukemia virus neonatally injected mice.
    Collavo D; Zanovello P; Biasi G; Chieco-Bianchi L
    J Immunol; 1981 Jan; 126(1):187-93. PubMed ID: 6969741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective effect of immune sera against transplantable Moloney virus-induced sarcoma and lymphoma.
    Pearson GR; Redmon LW; Bass LR
    Cancer Res; 1973 Jan; 33(1):171-8. PubMed ID: 4734119
    [No Abstract]   [Full Text] [Related]  

  • 15. T cell-mediated immunity to oncornavirus-induced tumors. II. Ability of different T cell sets to prevent tumor growth in vivo.
    Leclerc JC; Cantor H
    J Immunol; 1980 Feb; 124(2):851-4. PubMed ID: 6243333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secondary in vitro generation of cytolytic T-lymphocytes (CTL's) in the murine sarcoma virus system. Virus-specific CTL induction across the H-2 barrier.
    Collavo D; Parenti A; Biasi G; Chieco-Bianchi L; Colombatti A
    J Natl Cancer Inst; 1978 Sep; 61(3):885-90. PubMed ID: 80457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of Moloney sarcoma virus-induced tumor growth by concanavalin A.
    Davis S; Redmon LW; Pearson GR
    Immunol Commun; 1975; 4(1):29-37. PubMed ID: 1090515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cell-mediated immunity to oncornavirus-induced tumors. I. Ly phenotype of precursor and effector cytolytic T lymphocytes.
    Leclerc JC; Cantor H
    J Immunol; 1980 Feb; 124(2):846-50. PubMed ID: 6243332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serochemotherapy against a Moloney virus-induced leukemia.
    Pearson GR; Redmon LW; Pearson JW
    Cancer Res; 1973 Aug; 33(8):1854-7. PubMed ID: 4578564
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunization with p30 enhances the growth of a rat Moloney sarcoma.
    Jones JM; Kennel SJ; Feldman JD
    J Immunol; 1977 Jan; 118(1):371-3. PubMed ID: 830759
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.